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Introduction
The advancement of new therapeutic agents for 
multiple sclerosis (MS) relies on well-designed 
clinical trials to establish their safety and efficacy. 
Over the last two decades, clinical trials in MS 
have established a success rate of 27%, defined as 
passing phase I, II, III and United States Food 
and Drug Administration (US FDA) approval, 
almost tripling the overall industry rate of 10%.1 
As a result of now having 15 approved disease-
modifying therapies (DMTs) for relapsing–remit-
ting MS (RRMS), there is a greater challenge to 
improve the existing options and to achieve pro-
longed remission. The increased availability of 
treatment along with revisions in the diagnostic 
criteria have changed the clinical trial population 
and restricted the implementation of placebo-con-
trolled trials. At the same time, an increased 
understanding of the pathophysiology and natural 
history of the disease have spurred the develop-
ment of new outcome measurements and refine-
ment of existing metrics. Despite numerous 
successes in advancing therapies for RRMS, 
similar progress has not been achieved for patients 
with progressive forms of MS (PMS), and previ-
ously failed trials in PMS have delineated the chal-
lenges that must be overcome to develop 
treatments for PMS. The design of MS trials must 
take its dynamic landscape into consideration and 
account for the differences between modern and 
historical trials. This article will review the chang-
ing characteristics of MS trial patients, the shift 
from placebo-controlled trials to active compara-
tor studies, and traditional and new outcome 
measurements. In addition, the challenges and 
progress in PMS trials will be discussed.
Changes in trial populations
The characteristics of RRMS trial populations 
have changed over time, largely in response to 
shifting methodologies in patient diagnosis and 
selection as well as the availability of multiple 
treatments. Patients in recent trials are presenting 
with lower disease activity and slower clinical pro-
gression.2 This is evident in the annualized relapse 
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rates (ARRs) in the treatment groups from histori-
cal trials between 1993–2002 that have ranged 
between 0.5 and 0.87 whereas subsequent mod-
ern-day trials have reported ARRs between 0.16 
and 0.37.3 While some of the reductions in relapse 
rates are likely due to the more rigid definitions in 
trials used to confirm relapses, there nevertheless 
appears a steady decline in the ARR over time. A 
report analyzing the ARR in RRMS trials over 
time demonstrated a reduction of 0.37 relapses in 
the treatment arms and 0.36 in the placebo arms 
over a 10-year study period.4 In addition, patients 
who were relapse-free in the placebo groups of 
RRMS trials experience a longer time to their first 
relapse.2 The trend of MS trial patients presenting 
with milder disease over time is a result of multiple 
processes. In this section, we explore the changes 
in the MS trial population and its implications.
Changes in diagnostic criteria
The MS diagnostic criteria and its subsequent 
revisions have made it easier to diagnose the dis-
ease and this has resulted in many patients receiv-
ing an earlier diagnosis.5,6 Since the 2010 revision 
of the McDonald criteria, a diagnosis of MS can 
be made in a single time frame, in which lesions 
on a single magnetic resonance imaging (MRI) 
scan can fulfill both criteria for dissemination in 
time (DIT) and dissemination in space (DIS). 
This contrasts with previous criteria in which the 
diagnosis required subsequent clinical presenta-
tions or MRI to fulfill DIT. The latest revision of 
the McDonald criteria in 2017 further broad-
ened the diagnostic parameters and included the 
presence of oligoclonal bands in the cerebrospi-
nal fluid to substitute for DIT when the initial 
MRI findings did not fulfill this requirement.7 In 
addition, cortical lesions, and symptomatic 
lesions excluding the optic nerve, may now be 
counted as MRI evidence of DIS or DIT. By 
broadening the diagnostic criteria, more patients 
are likely to be diagnosed earlier whereas they 
previously would not be diagnosed by an earlier 
version of the criteria.
A consequence of earlier diagnosis resulting from 
changes in diagnostic criteria is that the overall 
clinical course of MS appears to improve. The 
average MS patient today has milder disease 
compared with those diagnosed using the older 
criteria. However, this may have resulted in lead-
time bias, in which earlier diagnosis appears to 
improve the disease course as patients take longer 
to accumulate neurological disability. This would 
lower the ARR by providing an observed time 
with fewer relapses relative to the older defini-
tions, such as the Poser criteria. This lead-time 
bias would also lead to the appearance of less 
virulent disease, at least in the short term. 
Whether this is occurring is difficult to separate 
from potential confounders such as improved 
availability and efficacy of therapies.
Likewise, a portion of patients with clinically iso-
lated syndrome (CIS) who are at high risk of 
developing MS will have a diagnosis of MS under 
the new criteria. The reassignment of patients 
who are at a higher risk within the CIS group to 
those having milder disease in the MS group 
results in the improved overall prognosis of both 
groups, an effect known as the Will Rogers phe-
nomenon.8 This has been demonstrated since the 
first iteration of the McDonald criteria by a retro-
spective analysis showing that 50% of patients 
with CIS would progress into definite MS within 
a year by the 2001 McDonald criteria compared 
with only 20% under the previously used Poser 
criteria.9 Currently, there is no evidence as to 
whether the 2017 revision will select patients with 
less active disease. Recently, a retrospective anal-
ysis on reaching the diagnosis of MS under the 
latest revision of the McDonald criteria compared 
with the 2010 revision, concluded that the 2017 
revision expedites diagnosis without compromis-
ing diagnostic accuracy.10
Availability of treatment
The increasing availability of treatment for RRMS 
has also affected patient enrollment in trials. With 
multiple DMTs available, there are motivations 
for high-risk patients not to enroll in a clinical 
trial as these patients may opt to select a proven 
therapy rather than enroll in a trial and risk receiv-
ing a placebo or a medication with unknown 
safety or efficacy profiles. Likewise, patients cur-
rently involved in trials who experience a relapse 
may be rescued and removed from the trial to 
start a proven therapy, thus leaving those whose 
disease activity is relatively well-controlled during 
the trial period to complete the study. There are 
suggestions that over time, withdrawals from 
therapy have been increasing and even mandated 
on the occurrence of relapses or progression, thus 
reducing the opportunity to have subsequent out-
come events reducing the ARR and other event 
rates over the course of the study.
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On the other spectrum, patients who are treat-
ment nonresponders may be interested in seeking 
new options by enrolling in a trial. However, 
some trials exclude enrollment of patients with 
extensive exposure to prior DMTs.11,12
Additional considerations
Other factors have been proposed to account for 
the changing MS trial population. For example, 
increasing physician and patient awareness of the 
disease and accessibility to MRI scanning has led 
to earlier diagnosis and initiation of treatment.13,14 
Improved standards of care for MS and accessibil-
ity to DMTs have resulted in better overall man-
agement and thus, lower disease activity in the 
overall MS population. Modern-day trials allow 
patients to enroll closer to their time of diagnosis 
by reducing the requirement of the number of 
relapses prior to screening. Whereas most early tri-
als required at least two relapses over the course of 
2 years, many contemporary trials allow for enroll-
ment with just one relapse over the past year. In 
addition, recent trials use more stringent and 
objective definitions of relapse requiring evaluation 
by a neurologist and measurable increases in the 
Expanded Disability Status Scale (EDSS) func-
tional system subscores.15 Together, these changes 
further substantiate the shift of the MS trial popu-
lation towards milder disease activity.
Implications
The changing MS trial population complicates 
the comparison of results from different studies, 
especially those from different times.16 Assessing 
whether one DMT is superior to another is chal-
lenging without a head-to-head comparison of 
the two agents in a randomized controlled trial, 
yet it is impractical to conduct head-to-head stud-
ies of all available agents. As trial patients present 
with milder disease, it becomes more difficult to 
generate on-study changes with traditional 
designs, and therefore larger group sizes and 
longer study duration are required. At the same 
time, it is no longer practical to design studies 
based on assumptions drawn from historic trials. 
Studies that are designed and statistically pow-
ered according to findings from earlier trials may 
overestimate disease activity and underestimate 
the number of patients enrolled to be able to 
detect treatment differences. There is a need for 
more efficient designs and sensitive outcome 
measurements.
Trial designs
The rapid expansion of treatment options for 
RRMS has led to changes in clinical trial designs 
over time. The era of placebo-controlled trials to 
establish new DMTs has ended due to the ethical 
concerns when existing therapies are available, 
and new agents are now assessed through com-
parative studies using established DMTs. The 
increased costs of large trials and high demand for 
participants have spurred the need for more effi-
cient designs, while increased therapeutic options 
calls for pragmatic studies to determine the real-
world applicability. The strength and limitations 
of MS trial designs are summarized in Table 1.
The ethics of placebo in RRMS trials
New treatment options for RRMS have led to the 
decline of placebo-controlled trials due to the eth-
ics and marketing concerns of performing such 
studies when multiple effective therapies exist. 
The 1990s saw the approval of the first MS thera-
pies, including interferon β preparations and glat-
iramer acetate.17–19 These trials relied on the use 
of a placebo group to demonstrate the efficacy of 
the investigated agent. Subsequent pivotal phase 
III trials of new therapies incorporated a placebo 
group until the approval of alemtuzumab, which 
in 2014 became the first US-approved agent 
without comparison with a placebo.20,21 However, 
the ethics of using a placebo in MS trials have 
been in discussion since much earlier.
Following the availability of the first injectable 
DMTs, the National MS Society organized an 
international task force in 2000 to discuss and 
publish proceedings on the ethical use of placebos 
in MS trials, and its recommendations were fur-
ther revised in 2008.22,23 The group concluded 
that participation in placebo trials is still ethical for 
patients who decline or fail available agents or 
when established therapy is not available at the 
time, such as in PMS. In countries without access 
to any DMTs, placebos may also remain ethical, 
but active comparator trials still seem more appro-
priate. Some countries, such as Brazil, will not 
allow placebo-controlled trials if the trial is not 
conducted in the country originating the trial. In 
all cases, appropriate informed consent and infor-
mation on available therapies must be provided.
Controversies exist on whether placebo trials are 
justified, and despite recommendations restricting 
the use of placebo in RRMS trials, subsequent 
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phase III trials of fingolimod, teriflunomide, and 
dimethyl fumarate had approximately 1500 patients 
exposed to placebo treatment.24 Many researchers 
and organizations have taken a middle ground with 
regard to using a placebo when proven therapies 
are available.25 The continued use of a placebo is 
backed by claims of the changing natural history of 
MS and indication that data from previous placebo 
groups are no longer valid.26 However, as growing 
evidence surmounts to the detrimental effects of 
delaying initiation of DMT for RRMS, the use of a 
placebo in RRMS trials have ended.27
Active comparator designs
The past decade saw a gradual replacement of pla-
cebo designs by active comparator trials. The piv-
otal phase III trial of peginterferon β-1a marked 
the last placebo-controlled trial of a therapeutic 
agent for RRMS.28 Subsequent published phase 
III trials of daclizumab and ocrelizumab, as well as 
the recently concluded phase III trial for ozani-
mod, have been conducted with active compara-
tor arms.29,30 These trials have shown that active 
comparator studies are feasible to detect both the 
efficacy and superiority of new agents. On the 
other hand, the use of an active comparator arm 
instead of a placebo reduces on-study changes 
between both groups, resulting in more patients 
needed to observe a significant and meaningful 
treatment effect. Modern-day trials have reflected 
this change. Whereas early trials typically enrolled 
around 200 patients, modern trials have frequently 
enrolled more than 1000 patients. The increasing 
costs of conducting large-scale trials have put a 
strain on existing resources, and there is a need for 
more efficient designs.
Combination trials
Combination trials seek to answer the question of 
whether multiple therapies administered together 
have greater efficacy than either alone. Studies 
are designed on the premise of using different 
agents with complementary or synergistic mecha-
nisms of action.31 In this regard, the most rigor-
ous study to date examined the effects of 
glatiramer acetate and interferon β-1a adminis-
tered together, which did not show a benefit in 
using both drugs over the more effective agent, 
glatiramer acetate.32,33 Other studies combining 
DMTs with hormonal therapy34 or statins35 have 
shown mixed results. Significant drawbacks of 
employing combination trials include the poten-
tial antagonistic mechanisms of action among 
study agents, compounded costs and side effects, 
and increased size and complexity of the trial 
design.36 While these reasons have deterred 
Table 1. Advantages and disadvantages of MS trial designs.
Trial design Advantages Disadvantages
Placebo-controlled Most rigorous test of treatment efficacy; 
requires fewer participants than active 
comparator trials
No longer ethical in RRMS trials due to 
availability of proven therapies
Active comparator Alternative to placebo-controlled trials 
and still capable of detecting treatment 
effect
Requires increased sample size 
to detect significant treatment 
differences
Combination Potential to increase efficacy by 
combining therapies
Increased costs and side effects 
from added treatment; potentially 
antagonistic interactions; increased 
design complexity
Adaptive Flexible and efficient designs to reduce 
sample size, exposure to harmful or 
ineffective treatment, and trial duration
Requires detailed planning and review 
of interim data as well as sensitive 
short-term outcome measures
Pragmatic Real life evaluation of treatment 
effectiveness; high external validity; 
results are more likely to inform practice
Greater design challenges due to 
heterogeneity of treatment effect; 
larger sample size and duration 
needed to determine effectiveness
MS, multiple sclerosis; RRMS, relapsing–remitting MS.
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combination trials in MS, there may be a role in 
the future as we progress in understanding the 
disease pathophysiology and developing more 
therapeutic options.37
Adaptive designs
Adaptive designs offer flexible and efficient trial 
methods that allow for preplanned modification of 
the study protocol after an interim analysis. This 
allows for flexibility in cost and trial duration. While 
adaptive designs have seen use in other fields of 
medicine, current experience with adaptive designs 
in MS is just emerging. The phase II trial of siponi-
mod for PMS was the first and only published MS 
trial to date that employed an adaptive design to 
evaluate the safety and tolerability of the study 
agent and to determine its dose-efficacy response 
curve.38 The study randomized one cohort of 
patients to receive 10 mg, 2 mg, or 0.5 mg of the 
study agent or placebo and evaluated the outcome 
of combined unique active MRI lesions at month 3. 
An interim analysis was performed, and based on 
an estimation of which doses would be needed for 
the optimum dose–response characterization, a 
second cohort of patients were randomized to 
receive 1.25 mg and 0.25 mg of the study drug. 
Evidence for the further efficacy of siponimod was 
recently published in a double-blind randomized 
placebo phase III trial.39 The design of adaptive tri-
als demands meticulous planning and a detailed 
interpretation of the interim results and navigation 
of a complex review process. It also requires a sensi-
tive short-term outcome measure on which to base 
interim decisions and long-term outcomes to assess 
treatment efficacy. Adaptive designs for MS are 
nascent and their prevalence remains to be seen.
Pragmatic trials
As therapeutic options for MS broaden, there is a 
growing need for evidence demonstrating appli-
cability of clinical trial results to routine clinical 
practice. In contrast with explanatory trials, which 
measure efficacy under controlled settings, prag-
matic trials are designed to evaluate treatment 
effectiveness in the real-world setting, producing 
results that are more generalizable and applicable 
to clinical practice.40 Despite the distinction 
between explanatory and pragmatic trials, actual 
trials fall on a spectrum between the two catego-
ries as characterized the Pragmatic–Explanatory 
Continuum Index Summary (PRECIS) tool and 
its subsequent revision (PRECIS-2).41,42 The tool 
helps trialists to ensure their design decisions 
match the trial’s intended purpose.
Just as explanatory trials face the challenge of 
requiring a large sample size with enough follow-
up time to detect significant treatment effects, the 
issue is even greater in pragmatic trials when 
selection criteria and interventions are less con-
trolled. A purely pragmatic trial in MS is almost 
unattainable and will almost certainly include 
components towards the explanatory end of the 
spectrum. As adeptly summarized by Ford and 
Norrie in a publication of pragmatic trials in the 
New England Journal of Medicine, ‘a pragmatic 
approach to pragmatism would be to adopt the 
features of pragmatic trials whenever feasible and 
sensible and when such features do not compro-
mise trial quality and the ability to answer the 
clinical question of interest.’43
Traditional and new outcome measures
Relevant and sensitive outcome measures are key 
to the assessment of a new drug’s efficacy. 
Traditionally, phase II trials assess the short-term 
effects on MRI outcomes, while phase III designs 
focus on more overt clinical outcomes. While this 
model has standardized the development of the 
currently available DMTs, the outcome measures 
used are imperfect, largely due to the heterogene-
ity of the disease. The paradigm of the MRI in 
phase II may be limited to the mechanism of 
action of the DMTs; most, if not all, have 
addressed inflammation as the target. New drugs 
may require different measures either on MRI or 
other biomarkers. Variations in disease presenta-
tion across the population and even within an 
individual over time have led to challenges in the 
development of methods to assess treatment effi-
cacy. This is further complicated by the need to 
capture changes within a short clinical trial dura-
tion for a disease with a prolonged clinical course. 
Traditional clinical and imaging outcome meas-
ures continue to show utility in modern trials 
while new measures in advanced imaging out-
comes, biomarkers and composite outcomes have 
diversified options for choosing study endpoints. 
The advantages and disadvantages of outcomes 
measures in MS trials are summarized in Table 2.
Clinical outcome measures
Clinical outcomes play an important role as the 
primary endpoint of pivotal phase III trials. 
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Assessments of relapse and changes in the EDSS 
score have been the oldest and most widely used 
clinical outcome measures. They each capture 
distinct pathophysiologic processes of the disease. 
Whereas relapse rates measure inflammatory 
activity, changes in the EDSS reflect accumula-
tion of clinical disability from inflammatory or 
neurodegenerative disease processes. The EDSS 
is universally familiar to MS clinicians and 
accepted by regulators,44,45 but it is marked by 
shortcomings in its variability between examiners, 
heavy emphasis on walking, limited impact of cog-
nitive impairment and nonlinearity. The imper-
fections of the EDSS have led to the development 
of the MS functional composite (MSFC),46 which 
covers three major MS domains, can be assessed 
quickly and reliably, and gives a z-score on a con-
tinuous scale. However, z-scores are abstract and 
difficult to interpret clinically, which has limited 
the widespread use of the MSFC. Despite its 
imperfections, the EDSS currently remains the 
most accepted clinical outcome measure and will 
likely remain so for the near future. Recently, elec-
tronic scoring of the EDSS has been developed 
and has shown an increased consistency of EDSS 
scoring,47 and it has seen use in the phase III trials 
of ocrelizumab30 and siponimod.39
Over the past decade, patient-reported outcome 
(PRO) measures have increasingly been used as 
Table 2. Advantages and disadvantages of outcomes measurements in MS trials.
Outcome measure Advantages Disadvantages
EDSS Established and universally accepted 
clinical outcome measurement; familiar 
to clinicians and regulators
Inter-rater variability; heavy 
emphasis on walking; exclusion 
of cognitive impairment; 
nonlinear scale
MSFC High reliability, validity, and sensitivity; 
versatile in evaluating various levels of 
disability
z-scores are abstract and difficult 
to interpret
Patient-reported 
outcomes
Patient-centered assessment of disease 
or treatment impact
Inherently subjective; limited 
use in disease-modifying therapy 
efficacy trials
MRI lesions Objective and quantifiable; High 
sensitivity in detecting subclinical 
disease activity; particularly useful as 
primary outcome measures in phase II 
trials
Lesions do not reflect degree of 
clinical disability
Brain atrophy Correlations with disability and 
cognitive impairment; measurement of 
neurodegeneration
Requires longer time to detect 
atrophy changes; multiple 
variables may confound 
measurements
OCT Fast, inexpensive, noninvasive technique; 
association with neurodegeneration
Limited evaluation of central 
nervous system function and 
disease burden
Fluid biomarkers Provides insight into disease 
pathophysiology; detects ongoing disease 
process; easy to obtain from serum
No established biomarkers; 
current biomarkers lack 
specificity
Combined outcomes 
(NEDA-3 and NEDA-4)
Better predictive value for disability 
progression than individual measures 
can identify treatment response
Cannot measure specific 
outcomes; no standardized set of 
components
EDSS, Expanded Disability Status Scale; MRI, magnetic resonance imaging; MS, multiple sclerosis; MSFC, multiple 
sclerosis functional composite; NEDA-3, no evidence of disease activity including absence of new lesions, confirmed EDSS 
worsening and relapses; NEDA-4, as NEDA-3 in addition to absence of significant brain volume changes; OCT, optical 
coherence tomography.
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complements to objective clinical measures and 
provide important information on subjective out-
comes, such as evaluations of subjective symp-
toms, satisfaction with treatment, and quality of 
life.48–50 They offer an additional facet in the 
assessment of treatment risks and benefits. 
Nevertheless, the subjectivity of PROs typically 
limits their use to a secondary outcome measure 
for DMT investigations.51 Their use as primary 
outcomes for symptomatic therapies may be 
appropriate.
Neuroimaging outcome measures
Neuroimaging outcome measures provide addi-
tional information to supplement clinical meas-
urements of treatment efficacy. Most commonly 
used are MRI measurements of lesion load or 
atrophy, which provide objective and highly sen-
sitive measurements of current and past disease 
activity. Inflammatory activity can be quantified 
as focal lesions on T2 MRI sequences or T1 gad-
olinium-enhancing lesions and have shown a cor-
relation with relapse rate.52,53 This important 
metric has allowed for rapid development of 
DMTs for RRMS due to its use as the primary 
outcome in short-term phase II trials. The ability 
to detect reductions in lesions on MRI associated 
with treatment allows for quick progress into 
phase III trials.54 The accrual of disability as 
reflected by neurodegeneration is measured by 
brain atrophy. This has been commonly assessed 
either as total brain parenchymal volume or frac-
tional volume, defined as the ratio of brain paren-
chymal volume to total volume within the brain 
surface contour.
MRI outcome measurements have undergone 
refinement as the understanding of the disease 
process continues to develop. Composite imaging 
outcomes of combined unique active lesions have 
seen use in a growing number of trials to assess 
total new or enlarging T2 or gadolinium-enhanc-
ing lesions. Regional atrophy is increasingly 
explored as a more sensitive measurement of 
changes reflective of associated deficits, and areas 
of the thalamus and cerebellum may be more sen-
sitive to changes.55,56 Gray matter atrophy has been 
shown to have more clinical correlation than white 
matter atrophy and is more sensitive to changes.57
Optical coherence tomography (OCT) is a nonin-
vasive method to image the retina and character-
ize pathology of the optic nerve.58 By visualizing 
the unmyelinated axons of the retinal nerve fiber 
layer (RNFL), OCT can directly assess axonal 
injury. In MS patients, the RNFL is thinner than 
in healthy people, regardless of a previous history 
of optic neuritis, supporting its role as a unique in 
vivo model of neurodegeneration.59–62 OCT has 
been used as an outcome measure in a few clinical 
trials in PMS without evidence of neuroprotective 
effects.63–66 Despite its current lack of prevalence 
in clinical trials, OCT as a fast, inexpensive, and 
noninvasive approach to evaluate neurodegenera-
tion, continues to prompt further investigation 
into refining the method.
Advancements in imaging techniques have led to 
the development of new outcome measures. 
Magnetization transfer ratio (MTR) is an MRI 
technique used to assess tissue integrity by corre-
lating it with axonal loss in MS lesions. Whole 
brain MTR has been used in several tri-
als,28,63,64,67,68 while regional MTR has been used 
in the phase III trial of laquinimod for RRMS.69 
While imaging outcome measurements are not 
likely to replace clinical endpoints in trials, they 
provide important information that supplements 
data on the efficacy of novel agents.
Fluid biomarkers
Clinical and radiologic outcome measures have 
served as the cornerstone of assessing the thera-
peutic efficacy of drugs and disease activity; how-
ever, they provide limited assessment of the 
pathophysiological disease process, such as inflam-
mation, axonal injury, and demyelination. Early 
search for biomarkers in the spinal fluid of MS 
patients hoped to identify outcomes that could be 
used in trials, but these efforts have not yielded 
promising results. In recent years, several biomark-
ers for MS have shown potential for diagnosis, 
prognosis, monitoring disease activity and treat-
ment response.70 Although currently there are no 
established biomarkers in use in clinical trials, 
among the most promising is neurofilament light 
chain (NFL).71 NFL is a subunit of neurofilaments 
that compose the axonal and dendritic cytoskele-
ton. It is released during axonal injury, making it a 
marker of axonal damage.72 In addition to its pres-
ence in the cerebrospinal fluid, NFL can also be 
detected in the serum due to using the ultrasensi-
tive single molecule array (Simoa) technology.73,74 
Serum NFL has been shown to correlate with 
relapses, EDSS scores, MRI lesions, and brain and 
spinal cord atrophy,75–78 and its levels have shown 
Therapeutic Advances in Neurological Disorders 12
8 journals.sagepub.com/home/tan
a decrease in patients treated with DMTs.79–82 Its 
downside is the lack of specificity, and levels may 
be influenced by many comorbidities or condi-
tions. With an increased availability and under-
standing of NFL and disease activity, NFL may 
become the first fluid biomarker to be used to 
monitor therapeutic effects in future randomized 
clinical trials and we may eventually see its use in 
the clinical setting.
Combined outcome measures
Other new outcome measures have integrated 
domains to achieve a more holistic evaluation.83 
The concept of disease activity-free status in MS 
was first explored in the natalizumab phase III 
trial,84 and it was later defined as ‘no evidence of 
disease activity’ (NEDA) to reflect the absence of 
relapses and no progression of disability or new 
MRI activity. NEDA has been used in some phase 
II85,86 and phase III trials.20,21,32 The combination 
of outcome measures increased the predictive 
value of disability progression compared with indi-
vidual clinical or MRI metrics.87 The drawback of 
using NEDA lies in the inability to assess its effects 
on specific outcomes, since clinical and radiologi-
cal activity are all combined into one assessment 
that is heavily dependent on timing. Currently, 
NEDA is still undergoing refinement as it remains 
unclear which optimal components to include and 
how frequently they should be assessed. In addi-
tion, brain volume as a marker of neurodegenera-
tion has been proposed to be included in a revised 
measure referred to as NEDA-4.88 As the concept 
of NEDA continues to evolve, it becomes impor-
tant to establish standardized definitions to facili-
tate universal interpretation and demonstrate its 
validity and reliability across studies.
Clinical trials for progressive MS
While substantial progress has been made in the 
advancement of therapeutic options for RRMS, 
progress for PMS remains limited and treatments 
are much needed, and only recently has a DMT 
been approved for PMS.89 The challenges in 
advancing therapeutics in PMS arise from a lim-
ited understanding of the pathogenesis of PMS 
and difficulty defining and assessing the disease 
course, as well as apparent confounding with the 
aging process. This contrasts with the established 
trial methodology for RRMS in which changes in 
focal MRI lesions in phase II trials allow for the 
accurate prediction of clinical reductions in relapse 
rate in phase III trials. Trials for PMS do not have 
established enrollment criteria owing to the lack of 
a uniform clinical definition of the disease.90 
Currently, there are no sensitive markers of disease 
activity that can accurately capture the varying 
degrees of inflammatory activity in the setting of 
neurodegeneration. Due to the process of neuro-
degeneration and compartmentalized inflamma-
tion playing a key role in PMS, drugs with 
predominantly systemic anti-inflammatory activity 
are less likely to be effective, especially in older 
patients where inflammatory activity has declined.
There is a heightened focus on clinical trials for 
PMS. Recently, The European Committee for 
Treatment and Research in MS (ECTRIMS) in 
association with the International Progressive MS 
Alliance held a workshop to address strategies for 
the advancement of trial design in PMS.91,92 The 
workshop addressed multiple aspects of trials for 
PMS and proceedings were published as a series of 
review articles in a themed issue of the Multiple 
Sclerosis Journal. The group recognized the grow-
ing importance of people with PMS in providing 
feedback and marketing and even in the design of 
trials.93 Patients now undertake a larger role than 
just participating in volunteer trials. They are 
involved in providing feedback in developing more 
clinically meaningful outcome measurements, 
advocating financial support, and serving as repre-
sentatives in the trial’s development committees.
The group recognized the pathophysiology of 
PMS as playing a key role in the trial design and 
therapy selection. The pathophysiology of PMS 
differs from RRMS in which systemic inflamma-
tion progresses to compartmentalized inflamma-
tion and neurodegeneration. The dynamic 
changes in pathophysiology over the course of the 
disease highlights the importance of identifying 
the disease stage and timing of intervention. 
Drugs with anti-inflammatory properties will 
have more benefit in patients with active inflam-
mation and are less effective in patients who have 
reached the late stages of neurodegeneration.94 
Enrollment of patients who have more active 
disease progression will likely have a greater 
sensitivity in detecting the treatments measuring 
progression than patients who do not progress. 
However, too narrow inclusion criteria will com-
promise the external validity and generalizability 
of results. More research to understand the 
pathophysiology and population characteristics of 
PMS are underway.
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Due to a current lack of early and sensitive meas-
urements of disease progression in PMS, an 
emphasis was placed on outcome measures. 
Clinical outcome measures such as the EDSS 
continue to serve as the established benchmark in 
PMS trials, but the shortcomings of EDSS limit 
its use alone as a sufficient outcome because of its 
near exclusive reliance in its upper ranges on 
walking and ignoring important functions such as 
cognitive and arm functions. Other measures 
have begun to surface that assess the vital clinical 
components of PMS. Together, these outcome 
measures address multiple facets of the clinical 
experience and are shaping trials to include a 
reworking and integration of new metrics such as 
composite measurements, cognition, and PROs.95 
The lack of a sensitive phase II trial outcome 
measure poses a limit to the timely advancement 
of potential therapeutic agents beyond their 
proof-of-concept phase. This contrasts with phase 
II trials for RRMS that employ focal MRI lesions 
to detect short-term changes. Currently, whole 
brain atrophy is the most accepted phase II out-
come measurement in PMS.96 However, there 
are notable limitations including slowness to 
change, inter-patient variability, and unidimen-
sional measurement. Other biomarkers in devel-
opment and testing, such as NFL, have begun to 
show promise.97
Despite challenges in PMS trials, there is progress 
in recent trials that have shown a positive effect in 
PMS including simvastatin,98 biotin,99 ocreli-
zumab,89 and siponimod.39 Potential evolution in 
the trials in PMS will focus on identifying agents 
targeting neuroprotection and remyelination, 
carefully identifying a study population with 
regards to baseline inflammatory activity, choos-
ing accurate and sensitive outcome measures in 
both phase II and III trials, and exploring the 
potential of adaptive designs.
Conclusion
The past 25 years have witnessed substantial 
developments in the treatment of MS. 
Advancements in therapeutic agents are a direct 
result of clinical trials that demonstrated their 
efficacy. Just as the disease course has been rede-
fined with the advent of DMTs, so have charac-
teristics of trials that continue to test new agents. 
The present-day MS trial population no longer 
shares the same baseline characteristics as his-
torical groups and is distinguished by earlier 
diagnosis and milder disease presentation due to 
increased availability of treatment. This change 
is present even in placebo groups, thus compli-
cating the comparison of data across trials. At 
the same time, active comparator designs have 
replaced placebo-controlled trials for RRMS, as 
the latter is no longer ethical in an era of proven 
therapeutic options. The head-to-head compari-
son of two agents has increased the required trial 
sample size and duration to be able to detect sig-
nificant on-study differences. This has moti-
vated consideration of more efficient study 
designs such as adaptive designs that have the 
potential to seamlessly transition from phase II 
to phase III trials, thus reducing the cost and 
expediting the trial process.
At the same time, new options for clinical and 
neuroimaging outcome measurements are begin-
ning to see use in trials to capture different aspects 
of the disease process. While traditional measures 
of relapse (e.g. changes in EDSS and focal MRI 
lesions) continue to remain the standard of assess-
ment of disease activity, new parameters such as 
brain volume, PROs, MTR, OCT, NFL have 
contributed new dimensions to capturing disease 
progression.
Amidst the successful development of DMTs for 
RRMS, increasing focus has turned towards clini-
cal trials for PMS where current therapies are 
limited and much needed. Experience with PMS 
trials has identified challenges in study design 
inherent in the nebulous characterization of the 
disease course and lack of sensitive measurements 
of disease progression. Unlike in RRMS where 
inflammatory activity can be assessed by relapses 
and lesion changes on MRI, there is no sensitive 
equivalent in measuring neurodegeneration and 
compartmentalized inflammation, which consti-
tutes significant mechanisms in the pathophysiol-
ogy of PMS. Nevertheless, recent research has 
shown positive results in multiple agents for the 
treatment of PMS, and outcome measures such 
as brain atrophy is an acceptable metric of neuro-
degeneration. Various agents in remyelination 
and neuroprotection are currently being tested, 
and the potential applications of adaptive designs 
are being explored.
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